We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Genentech has set a maximum yearly price of $340,000 for its recently approved spinal muscular atrophy drug Evrysdi (risdiplam), making the medicine notably less expensive than the other two SMA treatments on the market. Read More
The U.S. government’s $765 million loan to Eastman Kodak for a generic drug ingredient manufacturing facility aimed at reducing U.S. dependence on imports is on hold as federal investigators look into allegations of wrongdoing at the company. Read More
The World Health Organization (WHO) will need $100 billion to pay for COVID-19 vaccines but it has only received commitments for 10 percent of that amount, according to the organization’s Director General Tedros Adhanom Ghebreyesus. Read More
China-based CanSino Biologics is preparing a phase 3 trial of its COVID-19 vaccine in Saudi Arabia, the country’s Ministry of Health has announced. Read More
Gilead Sciences announced yesterday that it has filed a new drug application (NDA) with the FDA, seeking approval for remdesivir for the treatment of COVID-19 patients. Read More
The European Medicines Agency’s suspended the marketing authorizations of generic drugs tested by Panexcell Clinical Laboratories at its site in Mumbai, India. Read More
The European Medicines Agency (EMA) has updated its advice on impurity testing for nitrosamines, expanding it to include some biological medicines. Read More